News
GSK
49.56
-1.65%
-0.83
Gilead Sciences: From All-Time Highs To Higher Highs
Seeking Alpha · 17h ago
GSK Advances New First-in-Human Prostate Cancer Drug Into Early Clinical Testing
TipRanks · 23h ago
GSK Still Has Room To Run Despite Vaccine Cyclicality
Seeking Alpha · 1d ago
Summit Therapeutics. GSK collaborate on trial of ivonescimab
TipRanks · 1d ago
SUMMIT THERAPEUTICS: EACH PARTY TO MAINTAIN RIGHTS TO THEIR RESPECTIVE PRODUCTS, & AGREEMENT MUTUALLY NON-EXCLUSIVE
Reuters · 1d ago
Weekly Report: what happened at GSK last week (0105-0109)?
Weekly Report · 1d ago
Tempus AI (TEM) Tops $1.1B in Total Contract Value as Pharma Demand for AI Tools Surges
TipRanks · 1d ago
Peking University Resources Partners with Trivitron Healthcare to Launch Digital AI Platform
Reuters · 4d ago
Johnson & Johnson Wins Tariff Relief from Trump in a Drug Pricing Deal
TipRanks · 4d ago
UK Stocks-Factors to watch on January 9
Reuters · 4d ago
AnaptysBio Seeks Dismissal of Tesaro’s Breach Claim in Delaware Court
Reuters · 4d ago
ANAPTYSBIO INC - TRIAL IN ANAPTYS AND TESARO/GSK DISPUTE SET FOR JULY 14-17, 2026
Reuters · 4d ago
Upstream Bio: Fully Priced After Recent Rally
Seeking Alpha · 4d ago
Deutsche Bank Remains a Hold on GlaxoSmithKline (GSK)
TipRanks · 5d ago
Flu medication is in short supply in part of U.S. as cases soar
Seeking Alpha · 5d ago
LIVE MARKETS-Mixed reporting season ahead for European pharma
Reuters · 5d ago
GlaxoSmithKline (GSK) Receives a Buy from Jefferies
TipRanks · 5d ago
PRESS DIGEST-British Business - January 8 
Reuters · 5d ago
UBS Sticks to Their Hold Rating for GlaxoSmithKline (GSK)
TipRanks · 5d ago
GSK Advances Targeted Cancer Combo Trial, Keeping Its Oncology Pipeline in Focus
TipRanks · 5d ago
More
Webull provides a variety of real-time GSK stock news. You can receive the latest news about GSK PLC through multiple platforms. This information may help you make smarter investment decisions.
About GSK
GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.